Tapinarof Cream 1% Once Daily: Maintenance of Low Disease Activity Including Pruritus Through End of the Treatment-freeInterval in a Long-term Extension Trial in Patients Down to 2 Years of Age with Atopic Dermatitis
Bibliographic record
Abstract
- Tapinarof (VTAMA®, Dermavant Sciences, an Organon Company) is a non-steroidal, topical aryl hydrocarbon receptor (AhR)agonist approved by the FDA for the treatment of atopic dermatitis (AD) in adults and children down to 2 years of age, and for thetreatment of plaque psoriasis in adults2- Tapinarof binds to and activates AhR to restore the skin barrier by upregulating key barrier components, downregulatingpro-inflammatory cytokines associated with AD, and reducing oxidative stress (Figure 1)1- Discontinuation of topical therapy for AD may be associated with rapid return of disease1- Preventative maintenance with topicals may be a significant treatment burden for patients and caregivers1,3,4- In the ADORING 3 long-term trial, adults and children with AD received tapinarof cream 1% once daily (QD)5- Patients entered with or achieved complete disease clearance (51.9%; Validated Investigator Global Assessment for AtopicDermatitis™ [vIGA-AD™]=0) and clear or almost clear skin (81.6%; vIGA-AD™=0 or 1)5- After discontinuing tapinarof per protocol, patients maintained clear or almost clear skin for 79.8 (mean) consecutive days(first treatment-free interval)5
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".